116
|
346
|
6frpA |
Crystal structure of erk2 in complex with an adenosine derivative |
111
|
346
|
6fr1A |
Crystal structure of erk2 in complex with an adenosine derivative |
118
|
347
|
6g54A |
Crystal structure of erk2 covalently bound to sm1-71 |
116
|
345
|
6fj0A |
Crystal structure of erk2 in complex with an adenosine derivative |
108
|
345
|
6fleA |
Crystal structure of erk2 in complex with an adenosine derivative |
110
|
348
|
6gjdA |
Erk2 signalling protein |
112
|
346
|
6fjbA |
Crystal structure of erk2 in complex with an adenosine derivative |
119
|
345
|
6fi3A |
Crystal structure of erk2 in complex with an adenosine derivative |
117
|
346
|
6fjzA |
Crystal structure of erk2 in complex with an adenosine derivative |
108
|
346
|
6fi6A |
Crystal structure of erk2 in complex with an adenosine derivative |
112
|
350
|
6gjbA |
Erk2 signalling protein |
111
|
346
|
6fn5A |
Crystal structure of erk2 in complex with an adenosine derivative |
116
|
346
|
6fq7A |
Crystal structure of erk2 in complex with an adenosine derivative |
109
|
347
|
6qagA |
Erk2 mini-fragment binding |
106
|
347
|
6qa4A |
Erk2 mini-fragment binding |
106
|
347
|
6qawA |
Erk2 mini-fragment binding |
108
|
348
|
6qa1A |
Erk2 mini-fragment binding |
110
|
350
|
6qa3A |
Erk2 mini-fragment binding |
109
|
350
|
6q7kA |
Erk2 mini-fragment binding |
115
|
347
|
6qaqA |
Erk2 mini-fragment binding |
106
|
347
|
6qalA |
Erk2 mini-fragment binding |
107
|
347
|
6qahA |
Erk2 mini-fragment binding |
113
|
346
|
6q7sA |
Erk2 mini-fragment binding |
113
|
346
|
6q7tA |
Erk2 mini-fragment binding |
106
|
346
|
6fxvA |
Crystal structure of erk2 in complex with an adenosine derivative |
107
|
357
|
3sa0A |
Complex of erk2 with norathyriol |
110
|
345
|
5nhlA |
Human erk2 with an erk1/2 inhibitor |
109
|
345
|
5nhvA |
Human erk2 with an erk1/2 inhibitor |
116
|
348
|
5nhhA |
Human erk2 with an erk1/2 inhibitor |
112
|
347
|
5lcjA |
In-gel activity-based protein profiling of a clickable covalent erk 1/2 inhibitor |
116
|
350
|
5k4iA |
Crystal structure of erk2 in complex with compound 22 |
117
|
347
|
5hd4A |
Dissecting therapeutic resistance to erk inhibition rat wild type sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5-yl]pyrrolidine-3-carboxamide |
107
|
348
|
6gdqA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
107
|
347
|
6g9kA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
108
|
347
|
6ge0A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
110
|
347
|
6g93A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
110
|
350
|
6g91A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
109
|
350
|
6g9aA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
115
|
346
|
6g9mA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
104
|
347
|
6g8xA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
111
|
347
|
6g9nA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
113
|
350
|
6g92A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
102
|
349
|
6gdmA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
111
|
347
|
6g97A |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
108
|
350
|
6g9dA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
110
|
347
|
6g9hA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
105
|
350
|
6g9jA |
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2 |
108
|
339
|
6dcgA |
Discovery of mk-8353: an orally bioavailable dual mechanism erk inhibitor for oncology |
108
|
340
|
6cpwA |
Discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology |
115
|
350
|
5bvdA |
Tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase |